Molecular Partners AG (MOLN.SW) SIX
3.06
+0.05999994(+2.00%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
3.06
+0.05999994(+2.00%)
Currency In CHF
Address
Wagistrasse 14
Schlieren, 8952
Switzerland
Phone
41 44 755 77 00
Sector
Healthcare
Industry
Biotechnology
Employees
158
First IPO Date
March 03, 2015
| Name | Title | Pay | Year Born |
| Patrick Amstutz | Co-Founder, Chief Executive Officer, Member of Management Board & Director | 657,000 | 1975 |
| Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | 0 | N/A |
| Michael Tobias Stumpp | Co-Founder, Executive Vice President of Projects & Member of Management Board | 0 | 1972 |
| Pamela A. Trail | Strategic Consultant | 0 | 1956 |
| Martin Steegmaier | Chief Scientific Officer & Member of the Management Board | 0 | 1966 |
| Michael Pitzner | Executive VP of Partnering & General Counsel | 0 | N/A |
| Renate Gloggner | Executive Vice President of People & Community and Member of Management Board | 0 | 1970 |
| Alexander Zurcher | Chief Operating Officer & Member of Management Board | 0 | 1975 |
| Philippe Legenne | Chief Medical Officer & Member of the Management Board | 0 | 1966 |
| Daniel Steiner | Senior Vice President of Targeted Radio Therapeutics | 0 | N/A |
| Robert Hendriks | Senior VP of Finance & Member of Management Board | 0 | N/A |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.